Myxomatosis

Last updated

Myxoma virus
Myxoma virus (transmission electron microscope).jpg
Myxoma virus (transmission electron microscope)
Virus classification OOjs UI icon edit-ltr.svg
(unranked): Virus
Realm: Varidnaviria
Kingdom: Bamfordvirae
Phylum: Nucleocytoviricota
Class: Pokkesviricetes
Order: Chitovirales
Family: Poxviridae
Genus: Leporipoxvirus
Species:
Myxoma virus

Myxomatosis is a disease caused by Myxoma virus , a poxvirus in the genus Leporipoxvirus . The natural hosts are tapeti (Sylvilagus brasiliensis) in South and Central America, and brush rabbits (Sylvilagus bachmani) in North America. The myxoma virus causes only a mild disease in these species, but causes a severe and usually fatal disease in European rabbits (Oryctolagus cuniculus), the species of rabbit commonly raised for companionship and as a food source.

Contents

Myxomatosis is an example of what occurs when a virus jumps from a species adapted to the virus to a naive host, and has been extensively studied for this reason. [1] The virus was intentionally introduced in Australia, France, and Chile in the 1950s to control wild European rabbit populations. [2]

Cause

Wild rabbit with inflammation of eyes and nose caused by myxomatosis (Germany). Myxomatose 2.jpg
Wild rabbit with inflammation of eyes and nose caused by myxomatosis (Germany).

Myxoma virus is in the genus Leporipoxvirus (family Poxviridae ; subfamily Chordopoxvirinae ). Like other poxviruses, myxoma viruses are large DNA viruses with linear double-stranded DNA. Virus replication occurs in the cytoplasm of the cell. The natural hosts are tapeti (Sylvilagus brasiliensis) in South and Central America, and brush rabbits (Sylvilagus bachmani) in North America. The myxoma virus causes only a mild disease in these species, with signs limited to the formation of skin nodules. [3]

Myxomatosis is the name of the severe and often fatal disease in European rabbits caused by the myxoma virus. Different strains exist which vary in their virulence. The Californian strain, which is endemic to the west coast of the United States and Baja in Mexico, is the most virulent, with reported case fatality rates approaching 100%. [4] The South American strain, present in South America and Central America, is slightly less virulent, with reported case fatality rates of 99.8%. Strains present in Europe and Australia were originally introduced from South America but have become attenuated, with reported case fatality rates of 50–95%. While wild rabbits in Europe and Australia have developed some immunity to the virus, this is not generally true of pet rabbits. [5]

Transmission

Myxomatosis is transmitted primarily by insects. The myxoma virus does not replicate in these arthropod hosts, but is physically carried by biting arthropods from one rabbit to another. In North America mosquitoes are the primary mode of viral transmission, and multiple species of mosquito can carry the virus. [6] [7] [8] [9] In Europe the rabbit flea is the primary means of transmission. [10] Transmission via the bites of flies, lice, and mites have also been documented. [11] [10] Outbreaks have a seasonal nature and are most likely to occur between August and November, but cases can occur year round. [12] [13] Seasonality is driven by the availability of arthropod vectors and the proximity of infected wild rabbits. [14]

The myxoma virus can also be transmitted by direct contact. Infected rabbits shed the virus in ocular and nasal secretions and from areas of eroded skin. The virus may also be present in semen and genital secretions. Poxviruses are fairly stable in the environment and can be spread by contaminated objects such as water bottles, feeders, caging, or people's hands. [14] They are resistant to drying but are sensitive to some disinfectants. [15]

Pathophysiology

A laboratory study in which European rabbits received intradermal injections of a South American strain of the myxoma virus demonstrated the following progression of disease. Initially the virus multiplied in the skin at the site of inoculation. Approximately two days following inoculation the virus was found in nearby lymph nodes, and at three days it was found in the bloodstream and abdominal organs. At approximately four days the virus was isolated from non-inoculated skin as well as from the testes. Slight thickening of the eyelids and the presence of virus in conjunctival fluid was detectable on day five. Testicular engorgement was noticed on day six. [16]

Clinical presentation: South American strains of myxomatosis

European rabbit with skin nodules caused by myxomatosis (West Yorkshire, UK) Rabbit with Myxomatosis 1(RLH).jpg
European rabbit with skin nodules caused by myxomatosis (West Yorkshire, UK)

The clinical signs of myxomatosis depend on the strain of virus, the route of inoculation, and the immune status of the host. Signs of the classic nodular form of the disease include a subcutaneous mass at the site of inoculation, swelling and edema of the eyelids and genitals, a milky or purulent ocular discharge, fever, lethargy, depression, and anorexia. [14]

According to Meredith (2013), the typical time course of the disease is as follows: [3]

Days after infection Clinical signs
2–4Swelling at site of infection
4Fever
6Swelling of eyelids, face, base of ears, and anogenital area
6Secondary skin lesions, including red pinpoint lesions on eyelids and raised masses on body
6–8Clear ocular and nasal discharge that becomes mucopurulent and crusting
7–8 Respiratory distress
8–9 Hypothermia
10Complete closure of eyelids due to swelling
10–12Death

In peracute disease with a highly virulent strain, death may occur within 5 to 6 days of infection with minimal clinical signs other than the conjunctivitis. Death usually occurs between days 10 and 12.

In rabbits infected with attenuated, less virulent strains of the virus, the lesions seen are more variable and generally milder, and the time course is delayed and prolonged. Many rabbits will survive and the cutaneous lesions gradually scab and fall off, leaving scarring. A milder form of the disease is also seen in previously vaccinated domestic rabbits that have partial immunity. Vaccinated rabbits often present with localized scabbed lesions, frequently on the bridge of the nose and around the eyes, or multiple cutaneous masses over the body. They are often still bright and alert, and survive with nursing care. [3]

Respiratory signs are a common finding in rabbits that survive the first stages of myxomatosis. Mucopurulent nasal discharge occurs, leading to gasping and stertorous respiration with extension of the head and neck. Secondary bacterial pneumonia occurs in many cases. Chronic respiratory disease, such as nasal discharge, is common in surviving rabbits. Even in apparently recovered rabbits, it is not unusual to find lung lobes filled with fluid rather than air at necropsy. [14]

Since the 1970s an "amyxomatous" form of the disease has been reported in Europe which lacks the cutaneous nodules typical of myxomatosis. This form is clinically milder and generally nonlethal. Respiratory signs, including clear or purulent nasal discharge, predominate. Perineal edema, swollen eyelids, and purulent blepharoconjunctivitis are generally still present. This form has been observed in wild rabbits, but is significant mainly in farmed rabbits. [3]

Clinical presentation: North American strains of myxomatosis

Pet rabbit with myxomatosis caused by the MSW strain of myxoma virus (Santa Cruz, CA); note the swollen eyelids and genitals Myxomatosis in a pet rabbit.jpg
Pet rabbit with myxomatosis caused by the MSW strain of myxoma virus (Santa Cruz, CA); note the swollen eyelids and genitals

The distribution of Myxomatosis in North America is limited to the brush rabbit’s native habitat, which extends from the Columbia River in Oregon to the north, the Sierra Nevada and Cascade mountains to the East, and the tip of the Baja California peninsula to the south.[3] The brush rabbit is the sole carrier of myxoma virus in North American because other native lagomorphs, including cottontail rabbits and hares, are incapable of transmitting the disease.[4][1] Clinical signs of myxomatosis depend on the strain of virus, the route of inoculation, and the immune status of the host. Cases of myxomatosis in northern California, southern California, Oregon, and Mexico are caused by different strains of myxoma virus, and symptoms vary. All North American strains are highly virulent, with close to 100% case fatality rates.

California

Pet rabbit with myxomatosis caused by the MSW strain of myxoma virus (Santa Cruz, CA); note the facial swelling and subcutaneous edema 20190828 Myxomatosis MSW strain.jpg
Pet rabbit with myxomatosis caused by the MSW strain of myxoma virus (Santa Cruz, CA); note the facial swelling and subcutaneous edema

A 1931 paper reported twelve cases of myxomatosis from Santa Barbara, Ventura, and San Diego counties of California. Affected rabbits developed mucopurulent conjunctivitis and swelling of the nose, lips, ears, and external genitalia. Rabbits that survived for over a week developed cutaneous nodules on the face. [17]

A 2024 study found that myxomatosis caused by the MSW strain (California/San Francisco 1950) of the myxoma virus occurs regularly in the greater San Jose and Santa Cruz regions of California. Common physical examination findings included swollen eyelids, swollen genitals, fever, and lethargy. Swollen lips and ears and subcutaneous edema also occurred in some rabbits. Domesticated rabbits that spent time outdoors were at greater risk of acquiring the disease, and most of the cases occurred between August and October. It was postulated that the number of cases brought to veterinarians underestimated the total number of cases, as sudden death was sometimes the first sign noted. [13]

Oregon

A 1977 report from western Oregon described several cases of myxomatosis. The most common clinical signs observed were inflammation and swelling of the eyelids, conjunctiva, and anogenital region. Lethargy, fever, and anorexia were also observed. A single rabbit with confirmed myxomatosis eventually recovered. [18]

A 2003 report of a myxomatosis outbreak in western Oregon reported sudden death as a common finding. Also noted were lethargy, swollen eyelids, and swollen genital regions. [19]

Baja California

A 2000 report from the Baja Peninsula in Mexico described two outbreaks of myxomatosis in 1993. Affected domestic rabbits developed skin nodules and respiratory symptoms. [20]

Diagnosis

Because the clinical signs of myxomatosis are distinctive and nearly pathognomonic, initial diagnosis is largely based on physical exam findings. [21] [22] [23] If a rabbit dies without exhibiting the classic signs of myxomatosis, or if further confirmation is desired, a number of laboratory tests are available.

Histopathology

Tissues from rabbits suffering from myxomatosis show a number of changes on histopathology. Affected skin and mucous membranes typically show undifferentiated mesenchymal cells within a matrix of mucin, inflammatory cells, edema, and intracytoplasmic viral inclusion bodies. Spleen and lymph nodes are often affected by lymphoid depletion. Necrotizing appendicitis and secondary infections with gram-negative bacteria have also been described. [13] [18] [19]

Polymerase chain reaction

The development of molecular methods such as polymerase chain reaction (PCR) and real-time polymerase chain reaction assays has created faster and more accurate methods of myxoma virus identification. [24] PCR can be used on swabs, fresh tissue samples, and on paraffin-embedded tissue samples to confirm the presence of the myxoma virus and as well as to identify the viral strain. [25]

Other Testing

Other means of diagnosing myxomatosis include immunohistochemistry, electron microscopy, and virus isolation. Immunohistochemistry can demonstrate the presence of myxoma virus particles in different cells and tissues of the body. [13] [19] Negative-stain electron microscopic examination can be used to identify the presence of a poxvirus, although it does not allow specific verification of virus species or variants. [24] Virus isolation remains the "gold standard" against which other methods of virus detection are compared. Theoretically at least, a single viable virus present in a specimen can be grown in cultured cells, thus expanding it to produce enough material to permit further detailed characterization. [26]

Treatment

At present, no specific treatment exists for myxomatosis. Given that the mortality rate of North American strains of myxomatosis nears 100%, euthanasia is often recommended in the United States. [13] In other countries where less virulent strains are present and vaccines against the disease are available, supportive care may help rabbits to survive the infection. If treatment is attempted then careful monitoring is necessary to avoid prolonging suffering. Cessation of food and water intake, ongoing severe weight loss, or rectal temperatures below 37 °C (98.6 °F) are reasons to consider euthanasia. [14] [27]

Prevention

Vaccination

Vaccines against myxomatosis are available in some countries. All are modified live vaccines based either on attenuated myxoma virus strains or on the closely related Shope fibroma virus, which provides cross-immunity. It is recommended that all rabbits in areas of the world where myxomatosis is endemic be routinely vaccinated, even if kept indoors, because of the ability of the virus to be carried inside by vectors or fomites. In group situations where rabbits are not routinely vaccinated, vaccination in the face of an outbreak is beneficial in limiting morbidity and mortality. [3] The vaccine does not provide 100% protection, [14] so it is still important to prevent contact with wild rabbits and insect vectors. Myxomatosis vaccines must be boostered regularly to remain effective, and annual vaccinations are usually recommended. [3]

In Europe and the United Kingdom a bivalent vectored vaccine called Nobivac Myxo-RHD [28] is available that protects against both myxomatosis and rabbit haemorrhagic disease. This vaccine is licensed for immunization of rabbits 5 weeks of age or older, with onset of immunity taking approximately 3 weeks. Protection against myxomatosis and rabbit hemorrhagic disease has a duration of immunity for 12 months, and annual vaccination is recommended to ensure continued protection. The vaccine has been shown to reduce mortality and clinical signs of myxomatosis. [29]

Vaccination against myxomatosis is currently prohibited in Australia due to concerns that the vaccine virus could spread to wild rabbits and increase their immunity to myxomatosis. As feral rabbits in Australia already cause a great deal of environmental damage, this concern is taken seriously by the government. [30] Many pet rabbits in Australia continue to die from myxomatosis due to their lack of immunity. [31] There is at least one campaign to allow the vaccine for domestic pets. [32] The Australian Veterinary Association supports the introduction of a safe and effective myxomatosis vaccine for pet rabbits, [33] and the RSPCA of Australia has repeatedly called for a review of available myxoma virus vaccines and a scientific assessment of their likely impacts in the Australian setting. [34]

Although myxomatosis is endemic in parts of Mexico and the United States, there is no commercially available vaccine in either of these countries.

Other preventive measures

In locations where myxomatosis is endemic but no vaccine is available, preventing exposure to the myxoma virus is of vital importance. The risk of a pet contracting myxomatosis can be reduced by preventing contact with wild rabbits, and by keeping rabbits indoors (preferred) or behind screens to prevent mosquito exposure. Using rabbit-safe medications to treat and prevent fleas, lice, and mites is also warranted. New rabbits that could have been exposed to the virus should be quarantined for 14 days before being introduced to current pets.

Any rabbit suspected of having myxomatosis should be immediately isolated, and all rabbits in the area moved indoors. To prevent the virus from spreading further any cages and cage furnishings that have come into contact with infected rabbits should be disinfected, and owners should disinfect their hands between rabbits. Poxviruses are stable in the environment and can be spread by fomites but are highly sensitive to chemical disinfection; bleach, ammonia, and alcohol can all be used to deactivate myxoma virus. [35]

Reporting

Myxomatosis is a reportable disease in California, the United States, and in Mexico. [36] [37] [38] Veterinarians and pet owners who see this disease are encouraged to report all cases to the relevant agencies. Without accurate data on myxomatosis in North America, vaccine manufacturers will underestimate the need for a vaccine and be reluctant to produce one.

Use as a population control agent

Rabbit and myxomatosis introductions around the world with dates Map of myxomatosis introductions with dates.svg
Rabbit and myxomatosis introductions around the world with dates

Myxoma virus was the first virus intentionally introduced into the wild with the purpose of eradicating a vertebrate pest, namely the European rabbit in Australia and Europe. The long-term failure of this strategy has been due to natural selective pressures on both the rabbit and virus populations, which resulted in the emergence of myxomatosis-resistant animals and attenuated virus variants. The process is regarded as a classical example of host–pathogen coevolution following cross-species transmission of a pathogen. [39]

Australia

Rabbits around a waterhole in the myxomatosis trial site on Wardang Island, Australia in 1938 Rabbits MyxomatosisTrial WardangIsland 1938.jpg
Rabbits around a waterhole in the myxomatosis trial site on Wardang Island, Australia in 1938
Releasing the myxoma virus in Australia CSIRO ScienceImage 2232 Releasing the Myxoma Virus for Rabbits.jpg
Releasing the myxoma virus in Australia

European rabbits were brought to Australia in 1788 by early English settlers. Initially used as a food source, they later became feral and their numbers soared. In November 1937, the Australian Council for Scientific and Industrial Research used Wardang Island to conduct its first field trials of myxomatosis, which established the methodology for the successful release of the myxoma virus throughout the country. [40]

In 1950, the SLS strain of myxoma virus from the South American tapeti (Sylvilagus brasiliensis) was released in Australia as a biological control agent against feral rabbits. The virus was at first highly lethal, with an estimated case fatality rate of close to 99.8%. Within a few years, however, this strain was replaced by less virulent ones, which permitted longer survival of infected rabbits and enhanced disease transmission. The virus created strong selection pressure for the evolution of rabbits resistant to myxomatosis. As rabbits became more resistant the viral strains responded by becoming less virulent. [5] Rabbit hemorrhagic disease virus has also been used to control wild rabbit populations in Australia since 1995. [41]

Europe

In June 1952, Paul-Félix Armand-Delille, the owner of an estate in northwestern France, inoculated two wild rabbits with the Lausanne strain of myxoma virus. [42] His intention was to only eradicate rabbits on his property and town, but the disease quickly spread through Western Europe, Ireland and the United Kingdom. [1] Some dissemination of the virus clearly appeared deliberate, such as the introduction into Britain in 1953 and the introduction into Ireland in 1954. [43] Unlike in Australia, however, strenuous efforts were made to stop the spread in Europe. These efforts proved in vain. According to estimates, the wild rabbit population in the United Kingdom fell by 99%, in France by 90% to 95%, and in Spain by 95%. This in turn drove specialized rabbit predators, such as the Iberian lynx and the Spanish imperial eagle, to the brink of extinction. [44] [45]

Myxomatosis not only decreased the wild rabbit population and the population of its natural predators, but also had significant impacts on the large rabbit-farming industry, which produced domestic rabbits for meat and fur. [46] The Lausanne strain of the myxoma virus causes the formation of large purple skin-nodules, a sign not seen in other strains. As happened in Australia, the virus has generally become less virulent and the wild rabbit populations more resistant subsequently. [1]

New Zealand

The introduction of myxomatosis into New Zealand in 1952 to control a burgeoning rabbit problem failed for lack of a vector. [47]

South America

Two pairs of European rabbits set free in 1936 at Punta Santa Maria resulted in an infestation that spread over the northern half of Tierra del Fuego. More rabbits were introduced in 1950 near Ushuaia by the Argentinian Navy and a private rabbit farmer. The rabbits quickly became pests, riddling the ground with holes and leaving it bare of grass. By 1953 the rabbit population numbered about 30 million. In 1954 Chilean authorities introduced a Brazilian strain of myxoma virus to Tierra del Fuego, which succeeded in bringing rabbits to very low population levels. [48]

Use as an evolutionary model

Evolutionary history of the myxoma virus in Europe and Australia Evolutionary History of MYXV.tiff
Evolutionary history of the myxoma virus in Europe and Australia

Given the importance of viral evolution to disease emergence, pathogenesis, drug resistance, and vaccine efficacy, it has been well studied by theoreticians and experimentalists. The introductions of myxoma virus into European rabbit populations in Australia and France created natural experiments in virulence evolution. [49] While initial viral strains were highly virulent, attenuated strains were soon recovered from the field. These attenuated strains, which allowed rabbits to survive longer, came to dominate because they were more readily transmitted. As the complete genome sequences of multiple myxoma strains have been published, scientists have been able to pinpoint exactly which genes are responsible for the changes in the myxoma virus's virulence and behavior. [50]

However, the evolution of the disease has proved to be increasingly complex and unpredictable, both among various strains of host, and among strains of the virus. Both in modes of resistance and of virulence, and in all countries in which the virus has been introduced for control of feral rabbits, the hosts and the pathogens have continually adapted in various ways to evolutionary challenges. Although current strains of myxomatosis do not provide sufficient control on their own, the disease remains a significant ecological factor in rabbit control, both in Australia and in other countries. For example, in spite of long-term concern in Australia especially, where the initial virulence of myxomatosis declined after a few decades in the field, rabbit evolution of resistance to the disease has not gone unchallenged. For some recent strains of the virus, as a case in point, selection for reduced inflammation prolongs virus replication, which enhances transmission and reduces suppression of the virus by the host's fever; it also may cause immunosuppression, which favors high virulence. [51] Studies continue, both in the contexts of rabbit control, and of the relevant evolutionary principles.

In culture

Myxomatosis is referred to as "the white blindness" by the rabbit characters of the novel Watership Down (1972) by Richard Adams, and in the story a rabbit chief had driven out all rabbits who seemed to be afflicted. In one of the novel's folk tales about the rabbit hero El-ahrairah, the transmission of the disease is explained to him by the lord of the rabbit underworld, the Black Rabbit of Inle ("it is carried by the fleas in rabbits' ears; they pass from the ears of a sick rabbit to those of his companions"). [52]

The sixth album of British band Radiohead, Hail to the Thief , contains a song "Myxomatosis". The disease is used as analogy to the journalist attention the band has. Thom Yorke has said:

"I remember my parents pointing out all these dead rabbits on the road when I was a kid. I didn’t know that much about the virus, or even how to spell it, but I loved the word. I loved the way it sounded." [53]

Related Research Articles

<span class="mw-page-title-main">Rabbit</span> Mammals of the family Leporidae

Rabbits are small mammals in the family Leporidae, which is in the order Lagomorpha. They are familiar throughout the world as a wild prey animal, a domesticated form of livestock, and a pet, having a widespread effect on ecologies and cultures. The most widespread rabbit genera are Oryctolagus and Sylvilagus. The former, Oryctolagus, includes the European rabbit, Oryctolagus cuniculus, which is the ancestor of the hundreds of breeds of domestic rabbit and has been introduced on every continent except Antarctica. The latter, Sylvilagus, includes over 13 wild rabbit species, among them the cottontails and tapetis. Wild rabbits not included in Oryctolagus and Sylvilagus include several species of limited distribution, including the pygmy rabbit, volcano rabbit, and Sumatran striped rabbit.

<span class="mw-page-title-main">Rabbits in Australia</span>

European rabbits were first introduced to Australia in the 18th century with the First Fleet, and later became widespread, because of Thomas Austin. Such wild rabbit populations are a serious mammalian pest and invasive species in Australia causing millions of dollars' worth of damage to crops. Their spread may have been enhanced through the emergence of strong crossbreeds.

Serial passage is the process of growing bacteria or a virus in iterations. For instance, a virus may be grown in one environment, and then a portion of that virus population can be removed and put into a new environment. This process is repeated with as many stages as desired, and then the final product is studied, often in comparison with the original virus.

Classical swine fever (CSF) or hog cholera is a highly contagious disease of swine. It has been mentioned as a potential bioweapon.

<span class="mw-page-title-main">Virulent Newcastle disease</span> Contagious viral avian disease

Virulent Newcastle disease (VND), formerly exotic Newcastle disease, is a contagious viral avian disease affecting many domestic and wild bird species; it is transmissible to humans. Though it can infect humans, most cases are non-symptomatic; rarely it can cause a mild fever and influenza-like symptoms and/or conjunctivitis in humans. Its effects are most notable in domestic poultry due to their high susceptibility and the potential for severe impacts of an epizootic on the poultry industries. It is endemic to many countries. No treatment for VND is known, but the use of prophylactic vaccines and sanitary measures reduces the likelihood of outbreaks.

Viral pathogenesis is the study of the process and mechanisms by which viruses cause diseases in their target hosts, often at the cellular or molecular level. It is a specialized field of study in virology.

Lymphocytic choriomeningitis (LCM) is a rodent-borne viral infectious disease that presents as aseptic meningitis, encephalitis or meningoencephalitis. Its causative agent is lymphocytic choriomeningitis mammarenavirus (LCMV), a member of the family Arenaviridae. The name was coined by Charles Armstrong in 1934.

Marek's disease is a highly contagious viral neoplastic disease in chickens. It is named after József Marek, a Hungarian veterinarian who described it in 1907. Marek's disease is caused by an alphaherpesvirus known as "Marek's disease virus" (MDV) or Gallid alphaherpesvirus 2 (GaHV-2). The disease is characterized by the presence of T cell lymphoma as well as infiltration of nerves and organs by lymphocytes. Viruses related to MDV appear to be benign and can be used as vaccine strains to prevent Marek's disease. For example, the related herpesvirus found in turkeys (HVT), causes no apparent disease in the birds, and continues to be used as a vaccine strain for prevention of Marek's disease.

Betaarterivirus suid 1, commonly Porcine reproductive and respiratory syndrome virus (PRRSV), is a virus that causes a disease of pigs, called porcine reproductive and respiratory syndrome (PRRS), also known as blue-ear pig disease. This economically important, panzootic disease causes reproductive failure in breeding stock and respiratory tract illness in young pigs.

Aujeszky's disease, usually called pseudorabies in the United States, is a viral disease in swine that is endemic in most parts of the world. It is caused by Suid herpesvirus 1 (SuHV-1). Aujeszky's disease is considered to be the most economically important viral disease of swine in areas where classical swine fever has been eradicated. Other mammals, such as cattle, sheep, goats, cats, dogs, and raccoons, are also susceptible. The disease is usually fatal in these animal species.

<i>Feline calicivirus</i> Species of virus

Feline calicivirus (FCV) is a virus of the family Caliciviridae that causes disease in cats. It is one of the two important viral causes of respiratory infection in cats, the other being Felid alphaherpesvirus 1. FCV can be isolated from about 50% of cats with upper respiratory infections. Cheetahs are the other species of the family Felidae known to become infected naturally.

<i>Myxoma virus</i> Species of virus

Myxoma virus is a poxvirus in the genus Leporipoxvirus. The two broad geographic types of myxoma virus are Californian and South American. Californian myxoma virus is found on the West Coast of the United States, the Baja Peninsula of Mexico, and the southwest coast of Canada. South American or Brazilian myxoma virus is found in South and Central America. South American myxoma virus circulates in the jungle rabbit or tapeti, whereas Californian myxoma virus circulates in the brush rabbit. In their native hosts, the viruses cause the formation of benign cutaneous fibromas rather than systemic disease.

<span class="mw-page-title-main">Rabbit hemorrhagic disease</span> Disease that affects wild and domestic rabbits

Rabbit hemorrhagic disease (RHD), also known as viral hemorrhagic disease (VHD), is a highly infectious and lethal form of viral hepatitis that affects European rabbits. Some viral strains also affect hares and cottontail rabbits. Mortality rates generally range from 70 to 100 percent. The disease is caused by strains of rabbit hemorrhagic disease virus (RHDV), a lagovirus in the family Caliciviridae.

Rabbitpox is a disease of rabbits caused by a virus of the genus Orthopoxvirus in the family Poxviridae, and closely related to vaccinia virus. Rabbitpox was first isolated at the Rockefeller Institute in New York in 1933, following a series of epidemics in the laboratory rabbits. It is an acute disease only known to infect laboratory rabbits as no cases have been reported in wild rabbits; it cannot infect humans.

Animal viruses are viruses that infect animals. Viruses infect all cellular life and although viruses infect every animal, plant, fungus and protist species, each has its own specific range of viruses that often infect only that species.

<span class="mw-page-title-main">Genetically modified virus</span> Species of virus

A genetically modified virus is a virus that has been altered or generated using biotechnology methods, and remains capable of infection. Genetic modification involves the directed insertion, deletion, artificial synthesis or change of nucleotide bases in viral genomes. Genetically modified viruses are mostly generated by the insertion of foreign genes intro viral genomes for the purposes of biomedical, agricultural, bio-control, or technological objectives. The terms genetically modified virus and genetically engineered virus are used synonymously.

<span class="mw-page-title-main">Animal vaccination</span> Process

Animal vaccination is the immunisation of a domestic, livestock or wild animal. The practice is connected to veterinary medicine. The first animal vaccine invented was for chicken cholera in 1879 by Louis Pasteur. The production of such vaccines encounter issues in relation to the economic difficulties of individuals, the government and companies. Regulation of animal vaccinations is less compared to the regulations of human vaccinations. Vaccines are categorised into conventional and next generation vaccines. Animal vaccines have been found to be the most cost effective and sustainable methods of controlling infectious veterinary diseases. In 2017, the veterinary vaccine industry was valued at US$7 billion and it is predicted to reach US$9 billion in 2024.

Autogenous vaccines, also called autologous vaccines, autovaccines, “self” or custom vaccines, are vaccines that are prepared by isolation and destruction of microorganisms in infected individuals and used to provide immunity to the same individual.

Vaccine resistance is the evolutionary adaptation of pathogens to infect and spread through vaccinated individuals, analogous to antimicrobial resistance. It concerns both human and animal vaccines. Although the emergence of a number of vaccine resistant pathogens has been well documented, this phenomenon is nevertheless much more rare and less of a concern than antimicrobial resistance.

<span class="mw-page-title-main">Rabbit health</span> Health of rabbits

The health of rabbits is well studied in veterinary medicine, owing to the importance of rabbits as laboratory animals and centuries of domestication for fur and meat. To stay healthy, most rabbits maintain a well-balanced diet of Timothy hay and vegetables.

References

  1. 1 2 3 Kerr, P; Liu, J; Cattadori, I; Ghedin, E; Read, A; Holmes, E (2015). "Myxoma Virus and the Leporipoxviruses: An Evolutionary Paradigm". Viruses. 7 (3): 1020–1061. doi: 10.3390/v7031020 . PMC   4379559 . PMID   25757062.
  2. Correa-Cuadros, JP; Flores-Benner, G; Muñoz-Rodríguez, MA; Briceño, C; Díaz, M; Strive, T; Vásquez, F; Jaksic, FM (2023). "History, control, epidemiology, ecology, and economy of the invasion of European rabbits in Chile: a comparison with Australia". Biological Invasions. 25 (2): 309–338. Bibcode:2023BiInv..25..309C. doi:10.1007/s10530-022-02915-2.
  3. 1 2 3 4 5 6 Meredith, A (2013). "Viral skin diseases of the rabbit". Veterinary Clinics of North America: Exotic Animal Practice. 16 (3): 705–714. doi:10.1016/j.cvex.2013.05.010. PMID   24018033.
  4. Silvers, L; Inglis, B; Labudovic, A; Janssens, PA; van Leeuwen, BH; Kerr, PJ (2006). "Virulence and pathogenesis of the MSW and MSD strains of Californian myxoma virus in European rabbits with genetic resistance to myxomatosis compared to rabbits with no genetic resistance". Virology. 348 (1): 72–83. doi:10.1016/j.virol.2005.12.007. PMID   16442580.
  5. 1 2 Kerr, PJ; Cattadori, IM; Rogers, MB; Fitch, A; Geber, A; Liu, J; Sim, DG; Boag, B; Eden, JS; Ghedin, E; Read, AF; Holmes, EC (2017). "Genomic and phenotypic characterization of myxoma virus from Great Britain reveals multiple evolutionary pathways distinct from those in Australia". PLOS Pathogens. 13 (3): e1006252. doi: 10.1371/journal.ppat.1006252 . PMC   5349684 . PMID   28253375.
  6. Grodhaus, G; Regnery, DC; Marshall, ID (1963). "Studies in the epidemiology of myxomatosis in California. II. The experimental transmission of myxomatosis in brush rabbits (Sylvilagus bachmani) by several species of mosquitoes". Am J Hyg. 77: 205–212. PMID   13950625.
  7. Marshall, ID; Regnery, DC; Grodhaus, G (1963). "Studies in the epidemiology of myxomatosis in California I. Observations on two outbreaks of myxomatosis in coastal California and the recovery of myxoma virus from a brush rabbit (Sylvilagus bachmani)". American Journal of Epidemiology. 77 (2): 195–204. doi:10.1093/oxfordjournals.aje.a120310.
  8. Regnery, DC; Marshall, ID (1971). "Studies in the epidemiology of myxomatosis in California. IV. The susceptibility of six leporid species to Californian myxoma virus and the relative infectivity of their tumors for mosquitoes". American Journal of Epidemiology. 94 (5): 508–513. doi:10.1093/oxfordjournals.aje.a121348. PMID   5166039.
  9. Regnery, DC; Miller, JH (1972). "A myxoma virus epizootic in a brush rabbit population". Journal of Wildlife Diseases. 8 (4): 327–331. doi:10.7589/0090-3558-8.4.327. PMID   4634525.
  10. 1 2 Ross, J; Tittensor, AM; Fox, AP; Sanders, MF (1989). "Myxomatosis in farmland rabbit populations in England and Wales". Epidemiology and Infection. 103 (2): 333–357. doi:10.1017/s0950268800030703. PMC   2249516 . PMID   2806418.
  11. Bertagnoli, S; Marchandeau, S (2015). "Myxomatosis". Revue Scientifique et Technique de l'OIE. 34 (2): 539–556. doi:10.20506/rst.34.2.2378. PMID   26601455.
  12. Farrell, S; Noble, PJM; Pinchbeck, GL; Brant, B; Caravaggi, A; Singleton, DA; Radford, AD (2020). "Seasonality and risk factors for myxomatosis in pet rabbits in Great Britain". Preventive Veterinary Medicine. 176: 104924. doi:10.1016/j.prevetmed.2020.104924. PMID   32114004.
  13. 1 2 3 4 5 Stern, HS; Biswell, E; Kiupel, M; Ossiboff, RJ; Brust, K (2024). "Epidemiologic, clinicopathologic, and diagnostic findings in pet rabbits with myxomatosis caused by the California MSW strain of myxoma virus: 11 cases (2022–2023)". Journal of the American Veterinary Medical Association. 262 (9): 1–11. doi: 10.2460/javma.24.02.0139 . PMID   38788762.
  14. 1 2 3 4 5 6 Kerr, P (2013). "Viral Infections of Rabbits". Veterinary Clinics of North America: Exotic Animal Practice. 16 (2): 437–468. doi:10.1016/j.cvex.2013.02.002. PMC   7110462 . PMID   23642871.
  15. "Disinfection". The Center for Food Security and Public Health. Retrieved 21 July 2019.
  16. Fenner, F; Woodroofe, GM (1953). "The pathogenesis of infectious myxomatosis: the mechanism of infection and the immunological response in the European rabbit (Oryctolagus cuniculus)". The British Journal of Experimental Pathology. 34 (4): 400–411. PMC   2073564 . PMID   13093911.
  17. Kessel, JF; Prouty, CC; Meyer, JW (1931). "Occurrence of infectious myxomatosis in southern California". Exp Biol Med (Maywood). 28 (4): 413–414. doi:10.3181/00379727-28-5342.
  18. 1 2 Patton, NM; Holmes, HT (1977). "Myxomatosis in domestic rabbits in Oregon". J Am Vet Med Assoc. 171 (6): 560–562. PMID   914688.
  19. 1 2 3 Löhr, CV; Kiupel, M; Bildfell, RJ (2005). "Outbreak of myxomatosis in domestic rabbits in Oregon: pathology and detection of viral DNA and protein". Veterinary Pathology. 42 (5): 680–729. doi:10.1177/030098580504200501.
  20. Licón Luna, RM (2000). "First report of myxomatosis in Mexico". J Wildl Dis. 36 (3): 580–583. doi:10.7589/0090-3558-36.3.580. PMID   10941750.
  21. Kerr P (2013). "Myxomatosis". In Mayer, J; Donnelly, TM (eds.). Clinical Veterinary Advisor: Birds and Exotic Pets. Elsevier Saunders. pp. 398–401.
  22. Smith MV (2023). "Urogenital diseases". In Smith, MV (ed.). Textbook of Rabbit Medicine (3rd ed.). Elsevier. pp. 314–331.
  23. Girolamo ND; Selleri P (2021). "Disorders of the urinary and reproductive systems". In Quesenberry, KE; Orcutt, CJ; Mans, C; Carpenter, JW (eds.). Ferrets, Rabbits, and Rodents (4th ed.). Elsevier. pp. 201–219.
  24. 1 2 MacLachlan, J (2017). Fenner's Veterinary Virology, 5th Edition. Elsevier. p. 158. ISBN   978-0-12-800946-8.
  25. Albini, S; Sigrist, B; Güttinger, R; Schelling, C; Hoop, RK; Vögtlin, A (2012). "Development and validation of a Myxoma virus real-time polymerase chain reaction assay". Journal of Veterinary Diagnostic Investigation. 24 (1): 135–137. doi:10.1177/1040638711425946. PMID   22362943.
  26. MacLachlan, J (2017). Fenner's Veterinary Virology, 5th Edition. Elsevier. p. 112. ISBN   978-0-12-800946-8.
  27. Wolfe, AM; Rahman, M; McFadden, DG; Bartee, EC (2018). "Refinement and successful implementation of a scoring system for myxomatosis in a susceptible rabbit ( Oryctolagus cuniculus ) Model". Comparative Medicine. 68 (4): 280–285. doi:10.30802/AALAS-CM-18-000024. PMC   6103426 . PMID   30017020.
  28. "Nobivac Myxo RHD". MSD Animal Health. Retrieved 20 July 2019.
  29. "Nobivac Myxo RHD Data Sheet". European Medicine Agency. Archived from the original on 20 July 2019. Retrieved 20 July 2019.
  30. "A Statement from the Chief Veterinary Officer (Australia) on myxomatosis vaccine availability in Australia". Australian Government Department of Agriculture. Retrieved 20 July 2019.
  31. "The Rabbit Sanctuary Myxomatosis Hotline". Myxomatosis. Retrieved 20 July 2019.
  32. "Myxo Campaign". Myxomatosis. Retrieved 20 July 2019.
  33. "Myxomatosis vaccination of pet rabbits". Australian Veterinary Association. Retrieved 20 July 2019.
  34. "Why can't I vaccinate my rabbit against Myxomatosis?". Royal Society for the Prevention of Cruelty to Animals. Retrieved 20 July 2019.
  35. Delhon, Gustavo (2022). "Poxviridae". Veterinary Microbiology. pp. 522–532. doi:10.1002/9781119650836.ch53. ISBN   978-1-119-65075-1.
  36. "List of Reportable Conditions for Animals and Animal Products" (PDF). Animal Health Branch. California Department of Food and Agriculture. Retrieved 27 October 2024.
  37. "Reportable Diseases, Infections, and Infestations List" (PDF). National Animal Health Reporting System. USDA Animal Plant and Health Inspection Service. Retrieved 27 October 2024.
  38. "Myxomatosis" (PDF). General Directorate of Animal Health, Mexico. Retrieved 27 October 2024.
  39. MacLachlan, J (2017). Fenner's Veterinary Virology, 5th Edition. Elsevier. p. 168. ISBN   978-0-12-800946-8.
  40. "Rabbits around a waterhole at the enclosed trial site at Wardang Island, 1938". National Archives of Australia. Retrieved 28 July 2019.
  41. Mahar JE, Read AJ, Gu X, Urakova N, Mourant R, Piper M, Haboury S, Holmes EC, Strive T, Hall RN (January 2018). "Detection and Circulation of a Novel Rabbit Hemorrhagic Disease Virus in Australia". Emerg Infect Dis. 24 (1): 22–31. doi:10.3201/eid2401.170412. PMC   5749467 . PMID   29260677.
  42. Davis, J. "Darwin's rabbit is revealing how the animals became immune to myxomatosis". Natural History Museum. Retrieved 14 August 2019.
  43. Bartrip, P (2008). Myxomatosis: A History of Pest Control and the Rabbit. London, UK: Tauris Academic Studies. ISBN   978-1845115722.
  44. Gil-Sánchez, JM; McCain, EB (2011). "Former range and decline of the Iberian lynx (Lynx pardinus) reconstructed using verified records". Journal of Mammalogy. 92 (5): 1081–1090. doi: 10.1644/10-MAMM-A-381.1 .
  45. Sánchez, B. "Action plan for the Spanish imperial eagle (Aquila adalberti) in the European Union" (PDF). European Commission. Retrieved 14 August 2019.
  46. Cadogan, S (23 March 2017). "How a thriving food industry faded away to nothing in the 1960s". The Irish Examiner. Cork. Retrieved 15 October 2017.
  47. Gumbrell, RC (1986). "Myxomatosis and rabbit control in New Zealand". New Zealand Veterinary Journal. 34 (4): 54–55. doi:10.1080/00480169.1986.35282. PMID   16031265.
  48. Jaksic, F (1983). "Rabbit and Fox Introductions in Tierra del Fuego: History and Assessment of the Attempts at Biological Control of the Rabbit Infestation". Biological Conservation. 26 (4): 369–370. Bibcode:1983BCons..26..367J. doi:10.1016/0006-3207(83)90097-6.
  49. Bull, JJ; Lauring, AS (2014). "Theory and Empiricism in Virulence Evolution". PLOS Pathogens. 10 (10): e1004387. doi: 10.1371/journal.ppat.1004387 . PMC   4207818 . PMID   25340792.
  50. Burgess, HM; Mohr, I (2016). "Evolutionary clash between myxoma virus and rabbit PKR in Australia". Proceedings of the National Academy of Sciences. 113 (15): 3912–3914. Bibcode:2016PNAS..113.3912B. doi: 10.1073/pnas.1602063113 . PMC   4839419 . PMID   27035991.
  51. Kerr, PJ; Cattadori, IM; Sim, D; Liu, J; Holmes, EC; Read, AF (2022). "Divergent Evolutionary Pathways of Myxoma Virus in Australia: Virulence Phenotypes in Susceptible and Partially Resistant Rabbits Indicate Possible Selection for Transmissibility". Journal of Virology. 96 (20): e0088622. doi:10.1128/jvi.00886-22. PMC   9599488 . PMID   36197107.
  52. Cassidy, A (2019). Vermin, Victims and Disease: British Debates Over Bovine Tuberculosis and Badgers. Springer Nature. p. 178. ISBN   9783030191863.
  53. "Myxomatosis". citizeninsane.eu. Retrieved 18 October 2023.

Further reading